Biopharmaceutical News and Research

RSS

Dompé enters definitive agreement to acquire Anabasis

Dompé, one of Italy's leading biopharmaceutical companies, announced today that it has entered into a definitive agreement to acquire 100% of Anabasis Srl, a privately held Italian research and development biopharmaceutical company, focused on ocular diseases.

28 Feb 2012

Rhei granted marketing approval for MuGard in China

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, diabetes, and RNAi, announced that its MuGard partner in China, Rhei Pharmaceuticals HK Ltd., received regulatory and marketing approval for MuGard in China from the State Food and Drug Administration, or SFDA, to treat oral mucositis in cancer patients.

24 Feb 2012

Biofund, Quintiles to expand clinical development services in Russia

Russian Venture Company Biofund, a Russian-based investment firm, and Quintiles, the world's leading biopharmaceutical services company, today announced a definitive agreement to support expansion of clinical development services within the Russian Federation, the world's ninth most populous country.

24 Feb 2012

BioLineRx BL-7010 may reduce gluten toxicity in patients with celiac disease

BioLineRx, a biopharmaceutical development company, announced the publication of pre-clinical results demonstrating that BL-7010, an orally available treatment for celiac disease, reduces gluten toxicity (the negative effect of gluten on the patient's body).

22 Feb 2012

NASDAQ notifies CytRx of non-compliance with minimum bid price requirement

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that, as anticipated, on February 15, 2012, the Company was notified by The NASDAQ Stock Market that because the Company has not regained compliance with the $1.00 minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2), the Company's common stock would be subject to delisting from The NASDAQ Capital Market unless the Company requests a hearing before a NASDAQ Hearings Panel.

18 Feb 2012

New preclinical data from Regulus' miR-21 study on kidney fibrosis

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that new preclinical data investigating the role of microRNA-21 (miR-21) in the treatment of kidney fibrosis has been published in the journal Science Translational Medicine.

17 Feb 2012

Preliminary results from Soligenix SGX201 Phase 1/2 trial on acute radiation enteritis

Soligenix, Inc., a development stage biopharmaceutical company, announced preliminary results today from a Phase 1/2 clinical trial evaluating SGX201, a time-release formulation of oral beclomethasone 17,21-dipropionate (oral BDP), for the prevention of acute radiation enteritis.

10 Feb 2012

Alexion acquires Enobia Pharma

Alexion Pharmaceuticals, Inc. today announced that the Company has completed its previously announced acquisition of 100% of the capital stock of Enobia Pharma Corp., a private biopharmaceutical company focused on the development of therapies to treat patients with ultra-rare and life-threatening genetic metabolic disorders.

7 Feb 2012

Soligenix reports positive results from preclinical studies of vaccine thermostabilization technology

Soligenix, Inc., a development stage biopharmaceutical company, announced today results from preclinical studies of its proprietary vaccine thermostabilization technology indicating that Soligenix is able to produce stable vaccine formulations using adjuvants, protein immunogens, and other components that ordinarily would not withstand long temperature variations exceeding customary refrigerated storage conditions.

6 Feb 2012

BioLineRx, Genoscience and RFS Pharma enter agreement for BL-8030 Hepatitis C treatment

BioLineRx, a biopharmaceutical development company, announced today it has signed a worldwide, exclusive license agreement with Genoscience and RFS Pharma to develop and commercialize BL-8030, an orally available treatment for Hepatitis C.

6 Feb 2012

FDA intends to grant Priority Review designation for ThromboGenics' ocriplasmin

ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announces that the FDA intended to grant its recently-submitted ocriplasmin BLA (Biological License Application) for Priority Review.

3 Feb 2012

Sartorius consolidated sales revenue increases to 733.1M for fiscal 2011

Sartorius, a leading international laboratory and process equipment provider, grew dynamically yet again in 2011 and significantly expanded its profitability. Both Group divisions reported highs in sales revenue and earnings.

From Sartorius 2 Feb 2012

Omeros, BioMed sign new 15-year lease agreement

BioMed Realty Trust, Inc. announced today the signing of a new 15-year lease with Omeros Corporation for BioMed's Waterfront Research Center property located in Seattle, Washington.

1 Feb 2012

NIAID, Aeras partner for Phase II clinical trial of TB vaccine

Aeras announces today that the National Institute of Allergy and Infectious Diseases (NIAID), part of the United States National Institutes of Health (NIH), has joined as a partner for a Phase II proof-of-concept clinical trial of a tuberculosis vaccine candidate jointly developed by Aeras and Dutch biopharmaceutical company Crucell.

1 Feb 2012

Sigma-Aldrich acquires BioReliance

Sigma-Aldrich Corporation, a leading Life Science and High Technology company, announced it has completed its acquisition of BioReliance Holdings, Inc., a leading provider of global biopharmaceutical testing services, from Avista Capital Partners for $350 million in cash, subject to normal post-closing adjustments.

31 Jan 2012

Prosensa secures €23M in new equity financing

Prosensa, the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet needs, announced today that it has raised €23 million in new equity financing.

25 Jan 2012

AstraZeneca donation to benefit poor and uninsured Americans

AstraZeneca, the global biopharmaceutical company, has donated $3.8 million worth of prescription medicines to AmeriCares for chronically ill Americans who rely on safety net clinics for their medical care. The donation is one of the largest AmeriCares received in the past year for its domestic aid deliveries.

25 Jan 2012

Genoscience, BioLineRx to develop and commercialize BL-8020 for HCV

BioLineRx, a biopharmaceutical development company, announced today it has signed a worldwide, exclusive license agreement with Genoscience, a French company focused on viral disease therapeutics, to develop and commercialize BL-8020, an orally available treatment for Hepatitis C.

24 Jan 2012

ARCA biopharma receives method patent for treatment with bucindolol based on genetic targeting

ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for cardiovascular diseases, today announced that the U.S. Patent and Trademark Office has issued a patent on methods for determining whether to administer or prescribe bucindolol to a patient based on whether the patient has a specific genotype - homozygous for the arginine 389 polymorphism in the beta-1 adrenergic receptor.

20 Jan 2012

PolyTherics announces acquisition of WEP

PolyTherics Limited, a provider of solutions to biopharmaceutical companies for the improvement of protein and peptide based drugs, is pleased to announce the acquisition of Warwick Effect Polymers, a provider of specialty biopolymers for the modification of biological products.

20 Jan 2012